Ephedra Litigation Could Threaten AER Preemption Provision – CRN’s Mister
This article was originally published in The Tan Sheet
Executive Summary
A court order overturning FDA's ban of ephedra could impact industry's ability to get federal preemption into a mandatory AER bill, Council for Responsible Nutrition President Steve Mister stated at the SupplySide East trade show and conference in Secaucus, N.J. May 3
You may also be interested in...
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."